Chongqing Beer released hepatitis B vaccine progress plate sealed in trading

NetEase Finance September 2 News Chongqing Beer Today (600132) disclosed the hepatitis B vaccine clinical trial of the latest progress.　　As at August 31, the "therapeutic (synthetic peptide) hepatitis B vaccine for the treatment of chronic hepatitis B was the center for the efficacy and safety of the Central Laboratory (Group leader Unit) of the People's Hospital of Peking University, randomized, double-blind, placebo-controlled phase II clinical trials are being conducted in clinical hospitals according to clinical trial protocols.　　Today, Chongqing Beer opened nearly 2%, and then a huge amount of lifting, seal the limit, turnover significantly enlarged. The report said that the "therapeutic (synthetic peptide) hepatitis B vaccine combined with entecavir for the treatment of patients with chronic hepatitis B was randomized and safe, taking the first hospital affiliated to the Medical College of Zhejiang University as the Central Laboratory (Group leader Unit). A clinical trial of double blind and multicenter Phase II clinical trials The participants were screened into group work,　　A total of 72 subjects were currently in the group. The study of hepatitis B vaccine of Chongqing Beer has been a holding subsidiary of Chongqing Jia Chen Biological Company in the implementation, so far the clinical progress has been smooth. There is a market analysis that the Chongqing beer is still in the development of hepatitis B vaccine business has great potential and value.